Please assess the completion status of the following clinical trial:

Trial Title: Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Man or woman, 18-65 years of age, inclusive~2. Able to provide informed consent and comply with all study procedures~3. Women of childbearing potential with a negative urine pregnancy test at screening and on adequate contraception~4. Chronic, non-malignant, painful condition, treated with long-acting opioid (methadone, OxyContin®, MS (Morphine Sulfate) Contin®, Kadian®, Avinza®, Fentanyl®, Opana® ER)~5. Opioid treatment for at least 3 months prior to screening at a minimum dose of 90 mg of morphine equivalents per day or 50 mcg of the fentanyl transdermal patch~6. Dose of opioid treatment stable for at least 1 week prior to screening and expected to be stable from screening through end of second testing~7. Weight at screening 100-300 pounds, inclusive~Exclusion Criteria:~1. Pregnant or breastfeeding~2. Gastrointestinal disorder or S/P gastrointestinal surgery impacting absorption of study medication (delayed gastric emptying, partial or complete gastrectomy)~3. Alcohol or substance abuse within 2 years of screening~4. Consumption of alcohol within 24 hours of a screening or testing visit~5. Consumption of xanthine-containing beverages (coffee, tea, coke) on the morning of a screening or testing visit~6. Impaired kidney or liver function (transaminase levels more than 3 times elevated; estimated creatinine clearance less than 50 mL/min)~7. Epworth sleepiness scale (ESS) score 16 or higher at screening~8. Medically concerning hypertension (≥ 160/100) or unstable cardiovascular illness~9. Any clinically significant illness that would interfere with study participation or put the subject at risk~10. Exposure to investigational medication within 30 days of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Oxymorphone ER 40 mg fed (Type: EXPERIMENTAL): Participants received 40 mg oxymorphone ER after a high-fat meal of approximately 1,010 kCal
- Oxymorphone ER 40 mg fasting (Type: EXPERIMENTAL): Participants received 40 mg oxymorphone ER after fasting for 8-12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).